BCL-2 AND P53 EXPRESSION IN CLINICALLY LOCALIZED PROSTATE CANCER PREDICTS RESPONSE TO EXTERNAL BEAM RADIOTHERAPY
- 1 July 1999
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 162 (1) , 12-17
- https://doi.org/10.1097/00005392-199907000-00003
Abstract
Purpose: Clinicians have long been hampered by the inability to distinguished patients with localized prostate cancer who will and will not respond to radiotherapy. In a significant proport...Keywords
This publication has 27 references indexed in Scilit:
- Different pathways for radiation-induced apoptosisInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Bcl-2 and Bax function independently to regulate cell deathNature Genetics, 1997
- The proto-oncogene Bcl-2 and its role in regulating apoptosisNature Medicine, 1997
- Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional updatePublished by American Medical Association (AMA) ,1997
- Changes in Biomarker Expression in the Development of Prostatic AdenocarcinomaBiotechnic & Histochemistry, 1997
- Elevated Levels of Apoptosis Regulator Proteins P53 and BCL-2 are Independent Prognostic Biomarkers in Surgically Treated Clinically Localized Prostate CancerJournal of Urology, 1996
- Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancerSurgery, 1996
- Radiation therapy for prostate cancer long-term results and implications for future advancesCancer, 1993
- p53 function and dysfunctionCell, 1992
- Radical Prostatectomy for Stage a Adenocarcinoma of the Prostate: Staging Errors and their Implications for Treatment Recommendations and Disease OutcomeJournal of Urology, 1991